Log In
Print
BCIQ
Print
Print this Print this
 

CMB305, ID-CMB305

  Manage Alerts
Collapse Summary General Information
Company Immune Design Corp.
DescriptionCombination of LV305, a lentiviral vector engineered to deliver antigen-encoding nucleic acids to dendritic cells in vivo, and G305, an immunotherapy comprised of recombinant cancer/testis antigen 1B (CTAG1B; NY-ESO-1) antigen and GLA-SE adjuvant
Molecular Target
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today